What you need to know about Johnson & Johnson’s 2023 transparency report The annual report has just been released—here are key takeaways that showcase the company’s commitment to creating a more sustainable, equitable and innovative healthcare system. Read more May 8, 2024 How robots...
2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* ? 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjusted earnings per share (EPS) of...
2023 Annual Report 2022 Annual Report 2021 Annual Report 2020 Annual Report 2019 Annual Report 2018 Annual Report 2017 Annual Report 2016 Annual Report 2015 Annual Report 2014 Annual Report 2013 Annual Report 2012 Annual Report 2011 Annual Report...
• 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* • 2024 Second-Quarter Earnings per share
Annual Report 2018 2017/18 was a good year for JM. We delivered what we said we would, and built foundations for future growth. Download the full report (PDF, 13MB) Full year results announcement Investing in our science World class science and technology is at our core. In a world ...
2023年,由于新冠疫苗和抗病毒药Paxlovid销量锐减,辉瑞让出了“第一药企”的宝座。强生凭借851.6亿美元的销售额重新登上王座。 从只有14名员工的小微企业到拥有超过13万名员工的跨国巨头,强生所经历的不仅仅是138年栉风沐雨,还有无数的探索与尝试、挑战与教训,今天让我们一起走进这家传奇药企—强生!
Duato said the strong pharmaceutical results and potential upcoming drug launches make J&J “very confident” it can meet the division’s 2025 annual sales target of $57 million. Kenvue results, talc litigation J&J said the consumer health business raked in $4.01 billion in sales for the quarter...
2023 Annual Report 2023 was a year of achievement and evolution for Johnson & Johnson. Learn more Meeting agenda Annual Shareholders Meeting agenda Learn more Rules of order & FAQ’s Rules of order for conduct Learn more Messages from our leaders Hear from our Chairman Joaquin Duato Read ...
系统标签: johnson 强生 annual repo earnings diluted 2002AnnualReportDescriptionoftheCompanyJohnson&Johnsonhas$36.3billioninsalesandistheworld’smostcomprehensiveandbroadlybasedmanufacturerofhealthcareproducts,aswellasaproviderofrelatedservices,fortheconsumer,pharmaceutical,andmedicaldevicesanddiagnosticsmarkets.Johnson&Joh...
Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic